<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7502021</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1200</journal-id>
<journal-id journal-id-type="nlm-ta">Biotechnol Bioeng</journal-id>
<journal-id journal-id-type="iso-abbrev">Biotechnol. Bioeng.</journal-id>
<journal-title-group>
<journal-title>Biotechnology and bioengineering</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-3592</issn>
<issn pub-type="epub">1097-0290</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27399645</article-id>
<article-id pub-id-type="pmc">6650146</article-id>
<article-id pub-id-type="doi">10.1002/bit.26045</article-id>
<article-id pub-id-type="manuscript">NIHMS1039045</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Microfluidic Blood-Brain Barrier Model Provides In Vivo-Like Barrier Properties for Drug Permeability Screening</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Ying I.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Abaci</surname>
<given-names>Hasan Erbil</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shuler</surname>
<given-names>Michael L.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<aff id="A1"><label>a</label>Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, 14853, USA.</aff>
</contrib-group>
<author-notes>
<corresp id="CR1">Corresponding author: Michael L. Shuler, 381 Kimball Hall, Ithaca, New York 14853-7202, Phone: 607 255-7577, Fax: 607 254-5375, <email>mls50@cornell.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>30</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>21</day>
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>23</day>
<month>7</month>
<year>2019</year>
</pub-date>
<volume>114</volume>
<issue>1</issue>
<fpage>184</fpage>
<lpage>194</lpage>
<!--elocation-id from pubmed: 10.1002/bit.26045-->
<abstract id="ABS1">
<p id="P1">Efficient delivery of therapeutics across the neuroprotective blood-brain barrier (BBB) remains a formidable challenge for central nervous system drug development. High-fidelity <italic>in vitro</italic> models of the BBB could facilitate effective early screening of drug candidates targeting the brain. In this study, we developed a microfluidic BBB model that is capable of mimicking <italic>in vivo</italic> BBB characteristics for a prolonged period and allows for reliable <italic>in vitro</italic> drug permeability studies under recirculating perfusion. We derived brain microvascular endothelial cells (BMECs) from human induced pluripotent stem cells (hiPSCs) and cocultured them with rat primary astrocytes on the two sides of a porous membrane on a pumpless microfluidic platform for up to 10 days. The microfluidic system was designed based on the blood residence time in human brain tissues, allowing for medium recirculation at physiologically relevant perfusion rates with no pumps or external tubing meanwhile minimizing wall shear stress to test whether shear stress is required for <italic>in vivo</italic>-like barrier properties in a microfluidic BBB model. This BBB-on-a-chip model achieved significant barrier integrity as evident by continuous tight junction formation and <italic>in vivo</italic>-like values of trans-endothelial electrical resistance (TEER). The TEER levels peaked above 4000 Ω·cm<sup>2</sup> on day 3 on chip and were sustained above 2000 Ω·cm<sup>2</sup> up to 10 days, which are the highest sustained TEER values reported in a microfluidic model. We evaluated the capacity of our microfluidic BBB model to be used for drug permeability studies using large molecules (FITC-dextrans) and model drugs (caffeine, cimetidine, and doxorubicin). Our analyses demonstrated that the permeability coefficients measured using our model were comparable to <italic>in vivo</italic> values. Our BBB-on-a-chip model closely mimics physiological BBB barrier functions and will be a valuable tool for screening of drug candidates. The residence time based design of a microfluidic platform will enable integration with other organ modules to simulate multi-organ interactions on drug response.</p>
</abstract>
<abstract abstract-type="graphical" id="ABS2">
<title>Graphical abstract</title>
<p id="P2">
<graphic orientation="portrait" position="anchor" xlink:href="nihms-1039045-f0005.jpg"></graphic>
</p>
</abstract>
<kwd-group>
<kwd>blood brain barrier</kwd>
<kwd>organ on a chip</kwd>
<kwd>human iPS cells</kwd>
<kwd>TEER</kwd>
<kwd>permeability</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>